Skip to main content

Table 2 SNPs taken a genome-wide association study on PD used for stratification of patients (omics+/− groups)

From: An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial

SNP Locus Effect allele MAF Odds Ratio
rs329648 MIR4697 T 0,46 1,15
rs34311866 TMEM175-GAK-DGKQ G 0,14 1,40
rs11868035 SREBF1-RAI1 A 0,49 0,97
rs14235 BCKDK-STX1B A 0,36 1,19
rs11060180 CCDC62 G 0,25 0,90
rs71628662 GBA-SYT11 T 0,01 0,40
rs199347 GPNMB C 0,48 0,97
rs12637471 MCCC1 A 0,34 0,67
  1. SNPs were taken from the study of Nalls et al. [6]. Only SNPs were taken into account with an in silico annotation to mitochondrial homeostasis. SNP: single nucleotide polymorphism. MAF: mean allele frequency